Superworth

National Vision price to free cash flow EYE

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Nov 2, 2026
27.6×
8-year median
31.3×
Against its 8-year history
40th
percentile: 0 is its lowest day, 100 its highest
8-year range
11.7× to 494×
Peer median
16.9×

National Vision's price to free cash flow is 27.6× as of Nov 2, 2026.

That is below its 8-year median of 31.3×, close to the middle of its last 8 years.

Over that time it ranged from 11.7× in Jun 2026 to 494× in Dec 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 16.9×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far27.6×11.7×31.1×
202526.8×22.7×42.9×
202431.0×21.1×78.0×
202339.2×34.5×313×
2022129×17.7×136×
202123.3×16.8×31.5×
202027.8×17.7×82.2×
201944.0×36.7×492×
2018442×403×494×

Against its peers

Companies in Medical - Instruments & Supplies nearest National Vision's size, closest first, today.

CompanyPrice to free cash flow
EYENational Vision27.6×
CDRECadre17.3×
STAAStaar Surgicaln/m
BVSBioventus11.7×
IARTIntegra Lifesciences12.3×
IRMDIradimed38.9×
LMATLemaitre Vascular25.2×
INSPInspire Medical Systems16.6×
UFPTUFP Technologiesn/m
MOVMovado10.0×
WRBYWarby Parker136×
Peer median16.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on National Vision

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.